Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Giorgio Minotti
This session on the cardiotoxicity of antineoplastic agents, with contributions by G. Minotti (Rome, IT), D. Leung (Liverpool BC, AU), T. Force (Philadelphia, US), G.W.A. De Keulenaer (Antwerp, BE), & P.M. Elliott (London, GB), summarized the state-of-the-art on molecular mechanisms and clinical correlates of cardiotoxicity induced by antitumor drugs. This session was well-received by a crowded audience. The speakers highlighted the multifactorial nature of cardiotoxicity mechanisms, and the complex interplay that occurs between the mode of action of a given drug and risk factors such as unfavourable lifestyle, comorbidities, and age. A recurrent theme was that cardiotoxicity may remain asymptomatic for months or years after a successful completion of chemotherapy regimens. Regrettably, the speakers and the attendees agreed that there have been little or no improvements in detecting early asymptomatic dysfunctions. Ecochardiography and echo-Doppler techniques do not always assist in uncovering such dysfunctions. Rest and stress Magnetic Resonance has only occasionally been adopted to obviate such limitations, and the diagnostic and prognostic value of circulating markers (troponin, natriuretic atrial peptides) await further validation. Such uncertainties translate into a lack of guidelines about how and when a cancer patient should be protected with e.g. beta blockers or ACE inhibitors. Further complexity is introduced by the rapidly expanding repertoire of targeted drugs, whether antibodies or small tyrosine kinase inhibitors. These were hoped to eliminate cardiac toxicity, but the experience gained with many of them shows that the goal of combining improved activity with reduced cardiotoxicity was not fully met. Thus, the state-of-the-art in Cardio-Oncology turned out to be a collection of unanswered questions and unmet goals that the speakers dissected with intellectual loyalty. Establishing an expert panel on these issues should be felt as a priority by scientific societies from both oncology and cardiology.
Cardiotoxicity of antineoplastic agents
This congress report accompanies a presentation given at the ESC Congress 2008. Written by the author himself/herself, this report does not necessarily reflect the opinion of the European Society of Cardiology.
© 2017 European Society of Cardiology. All rights reserved